Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

"Tenvie was purpose-built to apply deep biological and chemical insights to address critical disease pathways,” said Paul L. Berns, Managing Director at ARCH Venture Partners and Executive Chair of ...

Leyden Laboratories B.V. (the "Company" or "Leyden Labs") today announced it has raised $70M in funding to advance its ...

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

According to MoEngage’s Email Benchmark Report for 2025 and Beyond, personalized emails outperform the generic ones. The ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Funding will propel Leyden Labs' non-vaccine intranasal antibody programs to safeguard people from respiratory viruses. The programs are based on Leyden Labs' Mucosal Protection Platform utilizing ...

Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate ...

Results are due later this year. The round was co-led by new investors F-Prime Capital, Forbion, and Norwest Venture Partners, with backup from RiverVest Venture Partners, Red Tree Venture Capital ...